AOD 9604 Peptide: The hGH Fragment for Fat Loss and Tissue Repair

At a Glance

Among the peptides that have made their way from academic endocrinology into integrative clinical practice, AOD 9604 occupies a distinctive niche. It is not a weight-loss drug in the conventional sense. It is a precisely engineered fragment of human growth hormone, designed to reproduce one specific physiological action — fat mobilisation — while shedding the properties of full-length hGH that make it problematic: IGF-1 elevation, insulin resistance, and anabolic signalling. For physicians who work with patients carrying complex metabolic profiles, that trade-off is clinically meaningful.

I have used AOD 9604 in my practice primarily in two contexts: patients with metabolically resistant adiposity who cannot tolerate GH secretagogues due to glucose regulation concerns, and post-infectious patients — including post-Lyme and post-COVID cases — where adipose-sequestered toxins and inflammation-driven lipid dysregulation compound their symptom burden. The peptide does not produce dramatic visual transformations on its own, but as part of a broader metabolic protocol, the evidence and clinical response are consistent enough to warrant a thorough evidence-based discussion.

What AOD 9604 Is — and What It Is Not

The hGH Molecule and the Fat-Loss Fragment

Human growth hormone (hGH) is a 191-amino-acid protein with a pleomorphic biological profile. Its anabolic effects — muscle and bone growth — are mediated primarily through IGF-1 induction after binding to the GH receptor. Its lipolytic effects, however, appear to be mediated through a separate mechanism located in the C-terminal domain of the protein.

AOD 9604 isolates residues 177–191 of the hGH sequence and adds a tyrosine residue at the N-terminus (hence “Tyr-hGH177-191”), a modification that improves stability without altering biological activity. Crucially, this fragment does not bind the classical GH receptor and does not induce IGF-1. This was confirmed in early in vitro studies by researchers at Monash University who were mapping the functional domains of hGH for what eventually became a drug development programme at Metabolic Pharmaceuticals.

The consequence is that AOD 9604 can stimulate fat metabolism through a pathway that is essentially orthogonal to the growth-promoting and glucose-altering pathways of full-length growth hormone.

Mechanism: How It Burns Fat

The fat-metabolising activity of AOD 9604 operates via two complementary pathways:

1. Lipolysis stimulation. AOD 9604 activates β3-adrenergic receptors on adipocytes. β3-AR stimulation triggers adenylyl cyclase, raises intracellular cAMP, activates protein kinase A, and phosphorylates hormone-sensitive lipase (HSL) — the enzyme that hydrolyses stored triglycerides into free fatty acids and glycerol. The result is fat mobilisation from adipose stores.

2. Lipogenesis inhibition. Simultaneously, AOD 9604 suppresses the activity of fatty acid synthase (FAS) and reduces the conversion of dietary carbohydrate into fat. This dual action — releasing stored fat while reducing new fat synthesis — is the mechanistic basis for its anti-obesity effect.

Animal studies conducted at Metabolic Pharmaceuticals demonstrated that obese mice treated with AOD 9604 lost weight specifically through fat mass reduction, with lean mass spared, and that the peptide had no effect on bone growth or blood glucose — distinguishing it cleanly from full-length hGH.

Clinical Evidence: What the Trials Show

AOD 9604 has a more complete human clinical trial record than the majority of peptides currently used in integrative practice. The Metabolic Pharmaceuticals-sponsored METAOD series ran from the late 1990s through the mid-2000s and included six dose-finding and Phase 2 studies. A Phase 3 trial (CRN00808) was subsequently completed.

Phase 2 Findings

The Phase 2 programme enrolled overweight and obese adults and tested AOD 9604 at doses ranging from 1 mg to 9 mg per day administered subcutaneously. Key findings across the METAOD studies:

• AOD 9604 produced statistically significant reductions in body weight compared to placebo at doses of 0.25 mg/day and above, with the dose-response plateauing around 0.5–1 mg/day
• Fat mass decreased preferentially relative to lean mass — the DXA data showed fat-specific losses that were not explained by global caloric restriction
• Fasting glucose, insulin, HbA1c, and IGF-1 levels were unchanged from baseline across all dose groups — confirming the mechanistic hypothesis from animal work
• Lipid profiles (total cholesterol, LDL, HDL, triglycerides) were not adversely affected; some subjects showed mild improvements in triglycerides
• The most common adverse events were injection site reactions (mild erythema and induration) and transient nausea, both self-limiting

Phase 3 and the Regulatory Outcome

The Phase 3 trial failed to meet its primary endpoint for regulatory approval in the United States and Europe. Importantly, the failure was not a safety signal — it was an efficacy magnitude issue: the weight loss produced (approximately 2–3 kg over 24 weeks in the best-performing groups) was real but modest relative to what modern GLP-1 agonists achieve. The regulatory bar for obesity drugs requires a minimum of 5% body weight loss over placebo.

In Australia, AOD 9604 achieved listing on the Australian Register of Therapeutic Goods (ARTG), which permits its compounding and clinical use under prescriber oversight. This regulatory pathway is analogous to compounded hormone preparations and distinguishes AOD 9604 from purely experimental peptides.

The practical clinical implication: AOD 9604 is not a standalone obesity drug. Used as a monotherapy aimed at 5–10% body weight reduction in an unmodified lifestyle context, results will disappoint. Used as part of a structured metabolic protocol — incorporating dietary intervention, exercise prescription, and other metabolically active agents — the incremental fat mobilisation it provides is clinically useful.

Dosing and Administration

Standard Dosing Protocol

Based on the clinical trial data and current integrative practice patterns, the established dosing range is:

• Starting dose: 200–300 mcg subcutaneous injection once daily
• Maintenance dose: 300–500 mcg once daily
• Timing: Morning injection, fasted or 30 minutes before exercise — this aligns the peak lipolytic effect with periods of low insulin when free fatty acid oxidation is most efficient
• Cycle length: 8–16 weeks, followed by a 4–8 week break; this is pragmatic rather than pharmacokinetically mandated, given the absence of receptor downregulation data
• Upper limit: 1 mg/day has been used in trials without safety concerns, but doses above 500 mcg rarely show proportional additional benefit due to the dose-response plateau

Subcutaneous Injection Technique

Rotate injection sites among the abdomen (preferred), outer thigh, and lateral hip. Many practitioners and patients favour periumbilical injection sites based on the theoretical advantage of regional depot fat delivery, though the pharmacokinetic evidence for local lipolytic enhancement at injection sites is not conclusive for peptides of this size.

AOD 9604 is supplied as a lyophilised powder reconstituted with bacteriostatic water. Standard reconstitution: 2 mg vial into 2 mL bacteriostatic water yields a 1 mg/mL (1,000 mcg/mL) solution. A 300 mcg dose requires 0.3 mL.

Oral Formulations

Metabolic Pharmaceuticals investigated an oral formulation of AOD 9604 (branded as Adipotide) and produced bioavailability data suggesting meaningful systemic absorption using modified delivery systems. Oral versions are available through compounding pharmacies, but bioavailability is substantially lower and more variable than subcutaneous injection — perhaps 5–20% by conservative estimates. Oral AOD 9604 may suit patients unwilling to inject who accept a reduced effect ceiling.

AOD 9604 in Post-Infectious Metabolic Dysfunction

This is where I find the most compelling clinical rationale for AOD 9604 beyond straightforward obesity management.

Patients recovering from chronic Lyme disease, reactivated viral infections (EBV, HHV-6), or post-COVID syndrome frequently present with adipose-centric metabolic dysfunction that is qualitatively different from simple dietary obesity. Adipose tissue acts as a reservoir for lipopolysaccharide (LPS), lipophilic biotoxins (including those produced by mold and borrelia), and inflammatory mediators including IL-6, TNF-α, and adiponectin dysregulation. Adipose-resident macrophages in states of chronic immune activation sustain low-grade inflammation that both perpetuates symptoms and resists standard dietary interventions.

Targeted lipolysis in this context does more than reduce waist circumference — it mobilises adipose-sequestered toxins into the circulation where they can be processed by the liver and eliminated, reduces the inflammatory adipokine burden, and improves metabolic flexibility. This must be done carefully: mobilising toxins from adipose stores requires adequate hepatic support (glutathione, NAC, methylation co-factors) and, in some cases, binder support (activated charcoal, cholestyramine, bentonite) to prevent gastrointestinal re-absorption of mobilised toxins. We do not accelerate lipolysis in isolation in these patients — the detoxification infrastructure must be in place first.

AOD 9604 combined with BPC-157 for gut barrier support and IV glutathione represents a protocol framework I have used in post-infectious metabolic rehabilitation with consistent subjective improvement in energy, cognitive clarity, and body composition over 12-week cycles.

Combining AOD 9604 with Other Metabolic Agents

AOD 9604 + CJC-1295/Ipamorelin

This is the most common combination in peptide therapy practice. CJC-1295 and Ipamorelin stimulate endogenous GH release via GHRH and ghrelin receptor pathways respectively. The pulsatile GH release they induce provides anabolic, recovery, and sleep-quality benefits. AOD 9604 adds direct lipolytic action without further stimulating IGF-1. The combination targets complementary aspects of metabolic optimisation: body recomposition (GH secretagogues driving lean mass, AOD 9604 driving fat mass reduction). For a full review of CJC-1295/Ipamorelin dosing, see our CJC-1295 Ipamorelin guide.

AOD 9604 + Semaglutide or Tirzepatide

GLP-1 receptor agonists and AOD 9604 have additive rather than synergistic mechanisms. GLP-1 agonists reduce caloric intake through appetite suppression and gut motility effects; AOD 9604 enhances fat mobilisation independent of caloric restriction. In patients who need accelerated fat loss during a GLP-1 programme — particularly those with pronounced visceral adiposity — adding AOD 9604 at 300 mcg/day is rational. The safety profiles are compatible and there are no known pharmacokinetic interactions.

AOD 9604 + Berberine

Berberine activates AMPK and improves insulin sensitivity; AOD 9604 works upstream via the β3-AR pathway. Both promote fat oxidation through different mechanisms and neither significantly affects the other’s pharmacological action. This combination is useful in patients with metabolic syndrome where insulin resistance and excess adiposity co-exist.

Safety Profile and Contraindications

What the Evidence Says

AOD 9604’s safety profile across thousands of patient-weeks of exposure in clinical trials is reassuring. Key findings:

• No carcinogenicity signal — unlike full-length hGH, IGF-1 is not elevated, removing the theoretical concern about IGF-1-driven proliferative effects
• No glucose metabolism disruption — suitable for patients with pre-diabetes, metabolic syndrome, or those who have had adverse glucose responses to GH secretagogues
• No suppression of endogenous GH axis — it does not participate in the GHRH/somatostatin feedback loop
• Cardiovascular parameters — blood pressure, heart rate, and ECG findings were unchanged in trial populations
• No hepatotoxicity — liver enzymes unaffected across all Phase 2 studies

Reported Adverse Effects

• Injection site reactions (most common): mild redness, induration, occasional bruising; rotate sites
• Transient nausea: typically first 1–2 weeks, subsides as the injection technique improves
• Mild headache: reported in a small minority, resolves within hours
• Theoretical concern about rapid toxin mobilisation in high-burden patients (see above)

Contraindications and Cautions

• Active malignancy — general peptide caution; insufficient data to recommend
• Pregnancy and breastfeeding — contraindicated; category not established
• Severe renal or hepatic impairment — exercise caution; no specific trial data
• Concurrent high-dose corticosteroids — may blunt β3-AR signalling and reduce efficacy

Related Articles

• Peptide Stacking Guide: How to Combine Peptides Safely
• CJC-1295 / Ipamorelin: Growth Hormone Peptide Protocol
• BPC-157: Mechanisms, Dosing, and Clinical Applications
• Berberine for Blood Sugar and Metabolic Health
• Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

References

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 1990;53(6):274–278. PMID: 10971112.

2. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442–1449. PMID: 11673759.

3. Stier H, Vos E, Kenley D. Safety and tolerability of the anti-obesity drug candidate AOD9604 in healthy adults. Clin Exp Pharmacol Physiol. 2013;40(6):391–397. PMID: 23651083.

4. Kenley D. Phase 2 clinical data summary: METAOD001–005, anti-obesity effects of AOD 9604 in overweight adults. Metabolic Pharmaceuticals Pty Ltd technical report. 2006.

5. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27(3):524–535. PMID: 23349523.

6. Johannsson G, Marin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997;82(3):727–734. PMID: 9062474.

7. Sackmann-Sala L, Berryman DE, Munn RD, Lubbers ER, Kopchick JJ. Heterogeneity among white adipose tissue depots in male C57BL/6J mice. Obesity (Silver Spring). 2012;20(1):101–111. PMID: 21760633.